CEL-SCI Corporation Holds Clinical Investigator Meeting for 56 European Centers Participating in Ongoing Phase III Cancer Trial with Multikine
CEL-SCI Corporation announced today it has held the Investigator Meeting for the European clinical investigators participating in the ongoing Phase III clinical trial of CEL-SCI’s investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Inj.). The meeting had 108 participants from 56 clinical centers that are or will be participating in the Multikine Phase III clinical trial for head and neck cancer. These clinical centers come from 13 European countries. The Investigator Meeting for the clinical centers in the United States and...
View full press release